Why Is ARGENX SE ADR (ARGX) Stock Down Today?

Argenx SE ADR shares fell 11.83% to close at $818.63 on Thursday. The primary driver for the decline was the company’s decision to discontinue a late-stage clinical trial for its drug Vyvgart in patients with Sjögren’s disease. An independent committee recommended stopping the study after a futility analysis indicated the treatment was unlikely to meet its primary endpoints.

What Happened

Argenx announced it halted the Phase 3 trial of efgartigimod in Sjögren’s disease following the recommendation of an independent data monitoring committee. The decision effectively erased a potential $3.5 billion market opportunity for the biotechnology firm. The move triggered a sharp selloff, with the stock dropping 14.4% in intraday trading before settling at the close. The failure of this specific indication has also weighed on peers in the same drug class, such as Immunovant, which is developing a similar mechanism of action. Wells Fargo lowered its price target on the stock to $1,355 from $1,415, while H.C. Wainwright described the day as containing both good and bad news for the company. Legal notices have also emerged, with SueWallSt notifying investors of a pending investigation into the firm.

What The Data Shows

The stock printed 22 fresh 52-week lows on October 8, 2026, marking a significant deterioration in its price trend. Over the last eight sessions, ARGX has declined 14.9% from $961.96 to $818.63. The company currently holds a market capitalization of $58.8 billion and trades at a P/E ratio of 31.2. Trailing twelve-month revenue grew 70.3%, and the net margin stands at 32.3%. The 52-week range for the stock is $661.85 to $1,072.75. In terms of institutional and political activity, Senator Alan Armstrong disclosed a purchase of $1,001 to $15,000 in shares on March 30, 2026. This was the only congressional buy recorded in the last 90 days, with no sells disclosed.

What To Watch

Investors will monitor the broader impact of the trial discontinuation on Argenx’s pipeline and valuation. With the stock trading near its 52-week low, attention will turn to how the company reallocates resources and whether the core business remains resilient despite the loss of the Sjögren’s disease indication.